By Finance Pulse in Stock Market —

Wedbush Rates Rocket Pharmaceuticals 'Outperform' with $32 Target

Wedbush Securities has initiated coverage on Rocket Pharmaceuticals (RCKT) with an Outperform rating and a $32 price target, forecasting significant growth by 2025. Explore what makes Rocket a promising investment.

A sleek and modern illustration of a rising rocket against a backdrop of financial charts, symbolizi
Wedbush Rates Rocket Pharmaceuticals 'Outperform' with $32 Target

Wedbush initiated Rocket Pharmaceuticals (RCKT) with an Outperform rating and $32 price target, expecting a pivotal year in 2025.

Source